Global Autosomal Dominant Polycystic Kidney Disease (ADPKD) Market - 2023-2030

Global Autosomal Dominant Polycystic Kidney Disease (ADPKD) Market - 2023-2030

The Global Autosomal Dominant Polycystic Kidney Disease (ADPKD) Market reached US$ XX million in 2022 and is expected to reach US$ XX million by 2030, growing with a CAGR of XX% during the forecast period 2023-2030.

In autosomal dominant polycystic kidney disease, the PKD1 and PKD2 genes are mutated, which is an inherited and progressive syndrome characterized by the development of many fluid-filled kidney cysts. These cysts cause continuing kidney function decline by pressing on the nearby renal tissue.

Autosomal dominant polycystic kidney disease also includes autosomal recessive polycystic kidney disease, autosomal dominant polycystic liver disease, and an expanding spectrum of conditions known as hepatorenal fibrocystic disorders that are recessively inherited.

The market for ADPKD is significantly impacted by the disease's expanding incidence because it expands the patient base in need of care and therapy. The mechanisms of ADPKD and possible treatment targets are now better understood because to ongoing research in the field. New diagnostic techniques and therapy alternatives are being created as a result of these developments.

Market Dynamics: Drivers

The increasing research activities

The most prevalent monogenic condition, ADPKD, which affects 12 million people globally, typically results in chronic kidney failure. In September 2023, in a Phase 1b MAD research of RGLS8429 for the treatment of ADPKD, Regulus Therapeutics Inc., a biopharmaceutical firm specializing in the discovery and development of novel drugs targeting microRNAs, reported positive topline data from the first cohort of patients.

In addition, in March 2023, POXEL SA, a clinical-stage biopharmaceutical company, declared the preclinical results in autosomal dominant polycystic kidney disease (ADPKD) for PXL770, a novel, first-in-class direct adenosine monophosphate-activated protein kinase (AMPK) activator.

End-stage renal disease is still largely brought on by ADPKD, which is also linked to a significant amount of unmet medical needs. There is an urgent need for novel therapeutic strategies because tolvaptan, the only medication licensed for the treatment of ADPKD, has moderate efficacy and known risks.

Limited treatment options

Tolvaptan, along with other prospective therapies for ADPKD in the future, can be costly. Even in areas where they are approved, the high cost of these medications might make them difficult for many people to get. Disparities in treatment and care may result from this. Tolvaptan is one medication for ADPKD that has adverse effects and safety issues. These might restrict their use, especially in individuals with pre-existing diseases or those who cannot handle the side effects of the prescription.

Segment Analysis

The global ADPKD market is segmented based on treatment type, distribution channel and region.

The pain & inflammation treatment segment accounted for approximately 56.3% of the market share

Acute pain generally starts off suddenly and is very acute, like a stabbing agony. If they encounter a kidney stone, a burst cyst, or a urinary tract infection, people with ADPKD may have severe pain. A patient can experience issues that cause acute pain more frequently if their ADPKD worsens. The good news is that after receiving treatment, acute discomfort typically subsides within a few days. Months or years can pass before chronic pain stops. It could be very minor, like a lingering ache or dull discomfort, but it can also be very strong, like a stabbing pain.

Once the cause of acute pain is identified, it may typically be treated within days. For instance, you might require medical attention for a urinary tract infection, a burst or bleeding cyst, or a kidney stone. Ibuprofen, aspirin, and naproxen are examples of non-steroidal anti-inflammatory medications. They can lessen discomfort brought on by inflammation and edema. They may cause adverse effects, such as gastrointestinal issues, and if used repeatedly, they may impair kidney function. For this reason, non-steroidal anti-inflammatory drug use is typically discouraged in ADPKD patients for longer than a few days.

Codeine, tramadol, and morphine are examples of opioids. They are available in various strengths and are used for more intense pain. They are often intended to be used temporarily because to their numerous negative effects and potential for addiction. Opioids may make pain worse for some people. For these reasons, before writing you a long-term prescription for an opioid, your doctor would probably consult with other experts.

Geographical Analysis

North America accounted for approximately 41.7% of the market share in 2022

North America has been a dominant force in the ADPKD market. About 50% of ADPKD patients get end-stage renal disease by the time they are 60 years old because of excessive kidney cyst cell proliferation, a key pathological characteristic. With 1 in 400 to 1,000 cases (or roughly 140,000 patients in the US), ADPKD is the fourth most common cause of chronic kidney disease (CKD) and the kidney condition most frequently handed down via families.

More than 50% of ADPKD patients experience renal failure by age 50, which is then treated with dialysis or a kidney transplant. Tolvaptan, the only medication authorized to slow progression, has a poor tolerance and is linked to serious adverse liver events (polyuria).

COVID-19 Impact Analysis

The outbreak of the COVID-19 pandemic in late 2019 created unprecedented challenges for industries worldwide, including the ADPKD market. Many non-urgent medical procedures and visits were postponed or canceled during the COVID-19 pandemic in order to focus resources on COVID-19 patients. The diagnosis and management of patients with ADPKD may have been impacted by the delay in healthcare access, potentially exacerbating their disease.

Telemedicine and other remote healthcare services were more widely used as a result of the pandemic. Telemedicine consultations may have helped ADPKD patients manage their condition and lessen the necessity for in-person appointments.

By Treatment Type
• Pain & Inflammation Treatment
• Kidney Stone Treatment
• Urinary Tract Infection Treatment
• Kidney Failure Treatment

By Distribution Channel
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

By Region
• North America
U.S.
Canada
Mexico
• Europe
Germany
UK
France
Italy
Russia
Rest of Europe
• South America
Brazil
Argentina
Rest of South America
• Asia-Pacific
China
India
Japan
Australia
Rest of Asia-Pacific
• Middle East and Africa

Competitive Landscape

The major global players in the market include Insmed Incorporated, Zambon S.p.A., CSL, CHIESI Farmaceutici S.p.A., Boehringer Ingelheim International GmbH, Armata Pharmaceuticals, Inc., Renovion, Inc. and others.

Key Developments
• In August 2022, Bayer introduced Finerenone under the trade name Kerendia. The use of finerenone, a non-steroidal, selective mineralocorticoid receptor antagonist, is recommended for those with type 2 diabetes and chronic kidney disease.
• In July 2022, Diaverum, a leading global provider of renal care services agreed to sell all of its Argentine renal care operations to Grupo Olmos by selling all of the company's shares in Diaverum Argentina S.A.

Why Purchase the Report?
• To visualize the global autosomal dominant polycystic kidney disease market segmentation based on treatment type, distribution channel, and region as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of autosomal dominant polycystic kidney disease market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as excel consisting of key products of all the major players.

The global autosomal dominant polycystic kidney disease market report would provide approximately 44 tables, 45 figures, and 186 Pages.

Target Audience 2023
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies